name: uncharacterized protein At3g60930, chloroplastic isoform 1 (Arabidopsis thaliana)

description: An uncharacterized protein At3g60930, chloroplastic (Arabidopsis thaliana) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9LEX8-1.


name: alpha-tocopherol transfer protein isoform 1 (rat)

description: An alpha-tocopherol transfer protein isoform 1 that is encoded in the genome of rat.


name: acetylcholine receptor subunit delta isoform 1 (human)

description: An acetylcholine receptor subunit delta isoform 1 that is encoded in the genome of human.


name: ACHD_HUMAN Acetylcholine receptor subunit delta (sprot)

description: An acetylcholine receptor subunit delta that is encoded in the genome of human.


name: acetylcholine receptor subunit delta, signal peptide removed form (human)

description: An acetylcholine receptor subunit delta (human) that has had the signal peptide removed. UniProtKB:Q07001, 22-517.


name: acetylcholine receptor subunit delta isoform h2 (human)

description: An acetylcholine receptor subunit delta (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q07001-2.


name: tumor necrosis factor ligand superfamily member 15 isoform 2 (human)

description: A tumor necrosis factor ligand superfamily member 15 isoform 2 that is encoded in the genome of human.


name: tumor necrosis factor ligand superfamily member 15 isoform 2

description: A tumor necrosis factor ligand superfamily member 15 that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O95150-2 or a 1:1 ortholog thereof.


name: E70E2_ARATH Exocyst complex component EXO70E2 (sprot)

description: A protein that is a translation product of the EXO70E2 gene in Arabidopsis thaliana.


name: RGL1_HUMAN Ral guanine nucleotide dissociation stimulator-like 1 (sprot)

description: A Ral guanine nucleotide dissociation stimulator-like 1 that is encoded in the genome of human.


name: Ral guanine nucleotide dissociation stimulator-like 1 isoform B (human)

description: A Ral guanine nucleotide dissociation stimulator-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NZL6-2.


name: Ral guanine nucleotide dissociation stimulator-like 1 isoform A (human)

description: A Ral guanine nucleotide dissociation stimulator-like 1 isoform 1 that is encoded in the genome of human.


name: UBA3_DICDI NEDD8-activating enzyme E1 catalytic subunit (sprot)

description: A NEDD8-activating enzyme E1 catalytic subunit that is encoded in the genome of Dictyostelium discoideum.


name: isoleucine--tRNA ligase, cytoplasmic methylated 1 (human)

description: An isoleucine--tRNA ligase, cytoplasmic (human) that has been methylated on the residue at the position equivalent to Cys-336 of the amino acid sequence represented by UniProtKB:P41252. UniProtKB:P41252, Cys-336, MOD:00660.


NRAM_I83A1 Neuraminidase (sprot)

A neuraminidase subtype N1 (Influenza A virus) that is encoded in the genome of the H1N1 strain A/Chile/1/1983.


name: extracellular matrix organizing protein FRAS1 isoform h5 (human)

description: An extracellular matrix organizing protein FRAS1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q86XX4-5.


name: putative colanic acid biosynthesis glycosyl transferase WcaA

description: A protein that is a translation product of the Escherichia coli K-12 wcaA gene or a 1:1 ortholog thereof.


name: WCAA_ECOLI Putative colanic acid biosynthesis glycosyl transferase WcaA (sprot)

description: A putative colanic acid biosynthesis glycosyl transferase WcaA that is encoded in the genome of Escherichia coli K-12.


name: BRISC complex subunit Abraxas 2 isoform 1

description: A BRISC complex subunit Abraxas 2 that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q15018-1 or a 1:1 ortholog thereof.


name: BRISC complex subunit Abraxas 2 isoform 1 (human)

description: A BRISC complex subunit Abraxas 2 isoform 1 that is encoded in the genome of human.


name: BRISC complex subunit Abro1 isoform 1 (mouse)

description: A BRISC complex subunit Abraxas 2 isoform 1 that is encoded in the genome of mouse.


ski-like protein isoform SNOA (human)

A ski-like protein (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P12757-2.


PRAX_RAT Periaxin (sprot)

A periaxin that is encoded in the genome of rat.


periaxin isoform 2 (rat)

A periaxin isoform 2 that is encoded in the genome of rat.


periaxin isoform r1 (rat)

A periaxin (rat) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q63425-1.


CIC-DUX4 Sarcoma

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and DUX4 gene on chromosome 4. The translocation results in CIC-DUX4, t(4;19)(q35;q13) fusions.


name: NUDE_ECOLI ADP compounds hydrolase NudE (sprot)

description: An ADP compounds hydrolase NudE that is encoded in the genome of Escherichia coli K-12.


name: HAUS augmin-like complex subunit 7 isoform h1 (human)

description: A HAUS augmin-like complex subunit 7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q99871-1.


Senile dementia

description: Loss of intellectual abilities in an elderly person, interfering with this person's activities.


histone H2AX deaminated 1 (mouse)

A histone H2AX (mouse) that has been deaminated on the residue at the position equivalent to Gln-113 of the amino acid sequence represented by UniProtKB:P27661. UniProtKB:P27661, Gln-113, MOD:00685.


protein THEM6 isoform 1 (mouse)

A UPF0670 protein THEM6 isoform 1 that is encoded in the genome of mouse.


UPF0670 protein THEM6 isoform 1

A UPF0670 protein THEM6 that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q80ZW2-1 or a 1:1 ortholog thereof.


protein THEM6 isoform 1 (rat)

A UPF0670 protein THEM6 isoform 1 that is encoded in the genome of rat.


name: mast/stem cell growth factor receptor Kit sequence variant V560G, signal peptide removed form (human)

description: A mast/stem cell growth factor receptor Kit (human) that has a Gly residue at the position equivalent to Val-560 of the amino acid sequence represented by UniProtKB:P10721-1 and that has had the signal peptide removed. Example: UniProtKB:P10721-1, 26-976, Val-560, CHEBI:29947.


name: LBO1_ARATH Protein LATERAL BRANCHING OXIDOREDUCTASE 1 (sprot)

description: A protein that is a translation product of the LBO1 gene in Arabidopsis thaliana.


phosphatidylethanolamine 32:0

A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 0 double bonds.


A phosphatidylethanolamine 32:0 zwitterion obtained by transfer of a proton from the phosphate to the amino group of 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine.


Cacosmia

description: A hallucination of an unpleasant odor.


KPYK2_ECOLI Pyruvate kinase II (sprot)

A pyruvate kinase II that is encoded in the genome of Escherichia coli K-12.


pyruvate kinase II

A protein that is a translation product of the Escherichia coli K-12 pykA gene or a 1:1 ortholog thereof.


name: pyruvate kinase II isoform 1, initiator methionine removed acetylated 1 (Escherichia coli K-12)

description: A pyruvate kinase II isoform 1, initiator methionine removed acetylated 1 in Escherichia coli K-12. UniProtKB:P21599-1, 2-480, Lys-351, MOD:00064.


name: pyruvate kinase II, initiator methionine removed form

description: A pyruvate kinase II that has had the initiator methionine removed.


name: pyruvate kinase II isoform 1 (Escherichia coli K-12)

description: A pyruvate kinase II isoform 1 that is encoded in the genome of Escherichia coli K-12.


name: pyruvate kinase II isoform 1, initiator methionine removed acetylated 1

description: A pyruvate kinase II isoform 1, initiator methionine removed form that has been acetylated at the position equivalent to Lys-351 of the amino acid sequence represented by UniProtKB:P21599-1. Example: UniProtKB:P21599-1, 2-480, Lys-351, MOD:00064.


name: pyruvate kinase II isoform 1, initiator methionine removed form

description: A pyruvate kinase II isoform 1 that has had the initiator methionine removed.


pyruvate kinase II isoform 1

A pyruvate kinase II that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P21599-1 or a 1:1 ortholog thereof.


name: bZIP transcription factor 29 isoform 2 (Arabidopsis thaliana)

description: A bZIP transcription factor 29 (Arabidopsis thaliana) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8H1F0-2.


name: BZP29_ARATH bZIP transcription factor 29 (sprot)

description: A protein that is a translation product of the BZIP29 gene in Arabidopsis thaliana.


name: bZIP transcription factor 29 isoform 1 (Arabidopsis thaliana)

description: A bZIP transcription factor 29 (Arabidopsis thaliana) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8H1F0-1.


LIPM_MOUSE Lipase member M (sprot)

A lipase member M that is encoded in the genome of mouse.


lipase member M

A protein that is a translation product of the human LIPM gene or a 1:1 ortholog thereof.


name: lipase member M, signal peptide removed form (human)

description: A lipase member M (human) that has had the signal peptide removed. UniProtKB:Q5VYY2, 34-423.


lipase member M isoform h2 (human)

A lipase member M (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5VYY2-2.


name: lipase member M phosphorylated 1 (human)

description: A lipase member M (human) that has been phosphorylated on the residue at the position equivalent to Ser-138 of the amino acid sequence represented by UniProtKB:Q5VYY2-1. Example: UniProtKB:Q5VYY2-1, Ser-138, MOD:00046.


lipase member M isoform h1 (human)

A lipase member M (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5VYY2-1.


lipase member M deaminated 1 (human)

A lipase member M (human) that has been deaminated on the residue at the position equivalent to Gln-84 of the amino acid sequence represented by UniProtKB:Q5VYY2-1. Example: UniProtKB:Q5VYY2-1, Gln-84, MOD:00685.


LIPM_HUMAN Lipase member M (sprot)

A lipase member M that is encoded in the genome of human.


Q20449_CAEEL Lipase (trembl)

A lipase member M that is encoded in the genome of worm.


name: interleukin-17 receptor E, signal peptide removed form (human)

description: An interleukin-17 receptor E (human) that has had the signal peptide removed. UniProtKB:Q8NFR9, 24-667.


name: PCKGC_RAT Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (sprot)

description: A phosphoenolpyruvate carboxykinase, cytosolic [GTP] that is encoded in the genome of rat.


name: phosphoenolpyruvate carboxykinase, cytosolic [GTP] isoform 1 (rat)

description: A phosphoenolpyruvate carboxykinase, cytosolic [GTP] isoform 1 that is encoded in the genome of rat.


ubinuclein-1 isoform m1 (mouse)

A ubinuclein-1 (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q4G0F8-1.


name: zinc finger protein 644 deaminated 2 (human)

description: A zinc finger protein 644 (human) that has been deaminated on the residue at the position equivalent to Gln-1277 of the amino acid sequence represented by UniProtKB:Q9H582-1. Example: UniProtKB:Q9H582-1, Gln-1277, MOD:00685.


name: CR021_HUMAN UPF0711 protein C18orf21 (sprot)

description: A UPF0711 protein C18orf21 that is encoded in the genome of human.


name: UPF0711 protein C18orf21 isoform h1 (human)

description: A UPF0711 protein C18orf21 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q32NC0-1.


name: UPF0711 protein C18orf21 isoform h2 (human)

description: A UPF0711 protein C18orf21 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q32NC0-2.


name: Y1725_ARATH Putative receptor-like protein kinase At1g72540 (sprot)

description: A protein that is a translation product of the At1g72540 gene in Arabidopsis thaliana.


aminodiol

An amino alcohol having two hydroxy functional groups.


An aminodiol that is propane-1,3-diol substituted ny an amino and a methyl group at position 2.


C20 sphingosine

A sphingoid that is the C20 analogue of sphingosine.


N-lauryldiethanolamine

An aminodiol that is dodecylamine in which the amino hydrogens are replaced by 2-hydroxyethyl groups.


C17 sphingosine

A sphingoid that is the C17 analogue of sphingosine.


A 2-aminooctadecene-1,3-diol having its double bond at position 4.


A sphingoid that is hexadecasphing-4-enine substituted at position 15 by a methyl group.


An aminodiol composed of any octadecene having hydroxy functional groups at positions 1 and 3 and an amino substituent at position 2.


A sphingenine in which the C=C double bond is located at the 8-position.


C20 sphinganine

A 2-aminoicosane-1,3-diol having (2S,3R)-configuration.


sphingenine

A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.


An aminodiol that is cyclohexane-1,2-diol substituted at positions 3 and 5 by amino groups (the 1S,2S,3R,5S-diastereomer)


L-erythro-sphingosine

A (2R,3S)-2-aminooctadec-4-ene-1,3-diol in which the double bond has E geochemistry.


A 2-aminooctadec-4-ene-1,3-diol having (2R,3S)-configuration.


DIMETHYLSPINGOSINE

A sphingoid that is sphingosine in which the two amino hydrogens are replaced by methyl groups.


N-ethyldiethanolamine

A aminodiol that is diethanolamine in which the amino hydrogen has been replaced by an ethyl group. It is a metabolite of nitrogen mustards.


A sphingenine in which the C=C double bond is located at the 4-position.


alpha-(hydroxymethyl)serine

A serine derivative in which the alpha-hydrogen of serine is replaced by a hydroxymethyl group.


A sphingoid that is sphingosine having an additional cis-double bond at position 14.


fingolimod

An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.


tetradecasphinganine

A sphingoid obtained by formal hydrogenation of the C=C bond of tetradecasphingosine


A sphingoid that is the C16 analogue of sphingosine.


tetradecasphingosine

A sphingoid that is the C14-analogue of sphingosine.


An aminodiol that is octadecane bearing two hydroxy substituents at positions 1 and 3 as well as an amino substituent at position 2.


A sphingoid that is hexadecasphinganine substituted at position 15 by a methyl group.


DIISOPROPANOLAMINE

A secondary amino compound that is diethanolamine substituted by methyl groups at positions 1 and 1'. It is a versatile chemical used in a variety of personal care, cosmetic and industrial products.


sphingosine

A sphing-4-enine in which the double bond is trans.


dihydrosphingosine

A 2-aminooctadecane-1,3-diol having (2S,3R)-configuration.


An aminodiol that is icosane bearing two hydroxy substituents at positions 1 and 3 as well as an amino substituent at position 2.


hexadecasphinganine

A sphingoid obtained by formal hydrogenation of the C=C bond of hexadecasphingosine.


name: cell surface glycoprotein CD200 receptor 1, signal peptide removed form (human)

description: A cell surface glycoprotein CD200 receptor 1 (human) that has had the signal peptide removed. Example: UniProtKB:Q8TD46-1, 29-325.


A lactone which is 9-methyl-1,5-dioxonane-2,6-dione substituted by a benzyl group at position 8, a [(3-hydroxy-4-methoxypyridine-2-yl)carbonyl]amino group at position 3 and a (2-methylbut-2-enoyl)oxy group at position 7. It is isolated from the mycelia cake of Streptomyces sp. 517-02 and exhibits potent antifungal activity.


name: corrinoid adenosyltransferase MMAB sequence variant R186W, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-186 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-186, CHEBI:29954.


corrinoid adenosyltransferase MMAB

A protein that is a translation product of the human MMAB gene or a 1:1 ortholog thereof.


name: MMAB_MOUSE Corrinoid adenosyltransferase MMAB (sprot)

description: A corrinoid adenosyltransferase MMAB that is encoded in the genome of mouse.


name: corrinoid adenosyltransferase MMAB sequence variant R191W, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-191 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-191, CHEBI:29954.


name: corrinoid adenosyltransferase MMAB isoform m2 (mouse)

description: A corrinoid adenosyltransferase MMAB (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9D273-2.


name: corrinoid adenosyltransferase MMAB sequence variant E193L, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Leu residue at the position equivalent to Glu-193 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Glu-193, CHEBI:30006.


name: corrinoid adenosyltransferase MMAB isoform m1 (mouse)

description: A corrinoid adenosyltransferase MMAB (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9D273-1.


name: MMAB_HUMAN Corrinoid adenosyltransferase MMAB (sprot)

description: A corrinoid adenosyltransferase MMAB that is encoded in the genome of human.


name: corrinoid adenosyltransferase MMAB, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250.


name: 5-hydroxytryptamine receptor 2A isoform h2 (human)

description: A 5-hydroxytryptamine receptor 2A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P28223-2.


name: SPT7_YEAST Transcriptional activator SPT7 (sprot)

description: A protein that is a translation product of the SPT7 gene in yeast.


name: chronic lymphocytic leukemia/small lymphocytic lymphoma

description: An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.


name: intrapelvic lymph node leukemic reticuloendotheliosis


refractory hairy cell leukemia

description: Hairy cell leukemia that is resistant to treatment.


name: pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

description: A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that lacks somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes, implying pregerminal center B-cell origin. Microarray gene expression profiling studies have demonstrated the expression of ZAP-70 gene (Syk family tyrosine kinase) in this subset of CLL/CLL. Patients with this variant of CLL/SLL have an unfavorable prognosis compared to those with somatic hypermutations of the IGH genes, with a median survival of approximately 6-8 years.


name: chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation

description: A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) expressing somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes. The recognition of this variant alters the belief that CLL/SLL is always derived from a naive, pregerminal center B-cell. The presence of somatic hypermutations of IGH genes occurs in approximately 50% of CLL/SLL cases and implies a postgerminal center, memory origin. Patients with this variant of CLL/SLL have a favorable prognosis, with a reported median survival of more than 24 years.


hairy cell leukemia variant

description: Hairy Cell Leukemia variant (HCL-V) is defined as a rare and indolent form of small, mature, B-cell leukemia characterized by splenomegaly, an elevated white blood cell (WBC) count and hyper-cellular bone marrow. HCL-V is more aggressive and resistant to therapy than classical HCL (HCL-C).


GAG_HV1B1 Gag polyprotein (sprot)

A lentivirus-type gag polyprotein that is encoded in the genome of Human immunodeficiency virus type 1 group M subtype B (isolate BH10).


name: protein turtle homolog A isoform h2 (human)

description: A protein turtle homolog A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9P2J2-2.


name: TUTLA_HUMAN Protein turtle homolog A (sprot)

description: A protein turtle homolog A that is encoded in the genome of human.


name: protein turtle homolog A isoform 1 (human)

description: A protein turtle homolog A isoform 1 that is encoded in the genome of human.


name: leucine-rich repeat and fibronectin type III domain-containing protein 1 isoform 1 (zebrafish)

description: A leucine-rich repeat and fibronectin type III domain-containing protein 1 (zebrafish) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6PGX3-1.


name: RL26_DICDI Large ribosomal subunit protein uL24 (sprot)

description: A protein that is a translation product of the rpl26 gene in Dictyostelium discoideum.


name: SNW domain-containing protein 1, initiator methionine removed form (human)

description: A SNW domain-containing protein 1 (human) that has had the initiator methionine removed. UniProtKB:Q13573, 2-536.


name: PDX2_DICDI Probable pyridoxal 5'-phosphate synthase subunit pdx2 (sprot)

description: A protein that is a translation product of the pdx2 gene in Dictyostelium discoideum.


name: Ras-related protein Rab-24 isoform 1 (mouse)

description: A Ras-related protein Rab-24 isoform 1 that is encoded in the genome of mouse.


Ras-related protein Rab-24 isoform 1

A Ras-related protein Rab-24 that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q969Q5-1 or a 1:1 ortholog thereof.


name: Ras-related protein Rab-24 isoform 1 (human)

description: A Ras-related protein Rab-24 isoform 1 that is encoded in the genome of human.


haptoglobin N-glycosylated 8 (human)

A haptoglobin (human) that has been N-glycosylated at the residue equivalent to Asn-184 of the amino acid sequence represented by UniProtKB:P00738-1, in which the glycan structure is represented by GlyTouCan:G31118FR. Example: UniProtKB:P00738-1, Asn-184, MOD:00160~GNO:G31118FR.


name: RS21_DANRE Small ribosomal subunit protein eS21 (sprot)

description: A small ribosomal subunit protein eS21 that is encoded in the genome of zebrafish.


name: small ribosomal subunit protein eS21 isoform 1 (zebrafish)

description: A small ribosomal subunit protein eS21 isoform 2 that is encoded in the genome of zebrafish.


name: large ribosomal subunit protein mL50 isoform h1 (human)

description: A large ribosomal subunit protein mL50 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8N5N7-1.


name: WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 isoform 1 (rat)

description: A WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 isoform 1 that is encoded in the genome of rat.


name: all trans-polyprenyl-diphosphate synthase PDSS2 isoform 1 (rat)

description: An all trans-polyprenyl-diphosphate synthase PDSS2 isoform 1 that is encoded in the genome of rat.


name: DLP1_RAT All trans-polyprenyl-diphosphate synthase PDSS2 (sprot)

description: An all trans-polyprenyl-diphosphate synthase PDSS2 that is encoded in the genome of rat.


name: partner and localizer of BRCA2 sequence variant W1140G (human)

description: A partner and localizer of BRCA2 (human) that has a Gly residue at the position equivalent to Trp-1140 of the amino acid sequence represented by UniProtKB:Q86YC2. UniProtKB:Q86YC2, Trp-1140, CHEBI:29947.


name: TEAD3_HUMAN Transcriptional enhancer factor TEF-5 (sprot)

description: A transcriptional enhancer factor TEF-5 that is encoded in the genome of human.


name: transcriptional enhancer factor TEF-5, initiator methionine removed form (human)

description: A transcriptional enhancer factor TEF-5 (human) that has had the initiator methionine removed. UniProtKB:Q99594, 2-435.


name: Gallbladder Cancer pN0 TNM Finding v6 and v7

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Gallbladder cancer with no regional lymph node metastasis. (from AJCC 6th and 7th Eds.)


name: Breast Classic Lobular Carcinoma In Situ Type B

description: Breast classic lobular carcinoma in situ  characterized by the presence of neoplastic cells with nuclei of various sizes and shapes.


breast cancer

description: A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.


name: Early Stage HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has not spread beyond the breast and the axillary lymph nodes.


name: Prognostic Stage IIIA Breast Cancer AJCC v8

description: Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma

description: A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.


Localized Breast Carcinoma

description: Breast carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Invasive Breast Cribriform Carcinoma

description: An invasive adenocarcinoma of the breast with a favorable clinical outcome, characterized by the presence of a sieve-like or cribriform infiltrating pattern.


name: Intraductal Micropapillary Breast Carcinoma

description: Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.


name: Solid papillary carcinoma in situ of breast

description: Breast solid papillary carcinoma characterized by the presence of nodules with rounded, well-circumscribed contours and a distribution pattern consistent with an in situ process. (WHO 2019)


Stage IIA Breast Carcinoma

description: Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Stage IIIC Breast Cancer AJCC v7

description: Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Recurrent Hormone Receptor-Negative Breast Carcinoma

description: The reemergence of hormone receptor-negative breast carcinoma after a period of remission.


breast angiosarcoma

description: A malignant vascular neoplasm arising from the breast.


name: Invasive Breast Lobular Carcinoma, Solid Variant

description: A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.


name: Metastatic Triple-Negative Breast Carcinoma

description: A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


name: Invasive Breast Lobular Carcinoma with Predominant In Situ Component

description: A breast carcinoma characterized by the presence of a predominant lobular carcinoma in situ component and a minor component of invasive carcinoma.


Recurrent Malignant Breast Neoplasm

description: The reemergence of a malignant breast neoplasm after a period of remission.


name: Invasive Breast Lobular Carcinoma, Alveolar Variant

description: A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.


Hereditary Female Breast Carcinoma

description: Breast carcinoma that has developed in female relatives of patients with history of breast carcinoma.


name: High Grade Ductal Breast Carcinoma In Situ

description: Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.


name: Breast Carcinoma Metastatic in the Liver

description: A carcinoma that originates from the breast and has spread to the liver.


name: Unresectable HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that is not amenable to surgical resection.


Recurrent Breast Mucinous Carcinoma

description: The reemergence of breast mucinous carcinoma after a period of remission.


Histiocytoid Breast Carcinoma

description: A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.


name: Squamous Cell Carcinoma In Situ of the Nipple

description: An intraepidermal squamous cell carcinoma involving the area of the nipple.


malignant neoplasm of breast stage I

description: Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0).  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T0: No evidence of primary tumor.  N0: No regional lymph node metastasis.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Prognostic Stage 0 Breast Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Locally Recurrent Breast Carcinoma

description: The reemergence of breast carcinoma after a period of remission, at or adjacent to the site of the original tumor.


name: Refractory HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that is resistant to treatment.


name: Invasive Breast Solid Papillary Carcinoma

description: Breast solid papillary carcinoma associated with areas featuring strands or large clusters of tumor cells. (WHO 2019)


Breast Florid Lobular Carcinoma In Situ

description: Breast lobular carcinoma in situ characterized by the presence of neoplastic cells with cytological features identical to classic lobular carcinoma in situ, but with marked distention of terminal ductal lobular units or ducts.


name: adenocarcinoma of breast with neuroendocrine differentiation

description: An invasive breast carcinoma characterized by the presence of focal neuroendocrine differentiation.


name: Metastatic Breast Inflammatory Carcinoma

description: Inflammatory carcinoma of the breast that has spread from its original site of growth to another anatomic site.


name: Metastatic Breast Neuroendocrine Tumor G1

description: A well differentiated neuroendocrine tumor that arises from the breast and has metastasized to other anatomic sites.


Stage IV Breast Cancer AJCC v6 and v7

description: Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)


name: Unresectable Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that is not amenable to surgical resection.


name: Breast Classic Lobular Carcinoma In Situ

description: Breast lobular carcinoma in situ characterized by the presence of dyscohesive proliferations of type A and/or type B epithelial cells. Type A cells are small cells with uniform hyperchromatic nuclei, whereas type B cells have slightly larger vesicular nuclei, with mild variability in size and shape and with small nucleoli. The cell populations may be mixed in individual proliferations. (WHO 2019)


Atypical Medullary Breast Carcinoma

description: An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.


name: Refractory Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that is resistant to treatment.


Breast Periductal Stromal Tumor

description: A rare, low-grade malignant stromal tumor that arises from the breast. It is characterized by the proliferation of atypical stromal spindle cells that surround benign tubules and ducts in a pericanalicular pattern. Mitotic activity is present. The tumor has a multinodular and infiltrative growth pattern and lacks the leaf-like architecture of phyllodes tumor. Wide excision with negative margins is the treatment of choice.


Primary angiosarcoma of breast

description: An angiosarcoma that arises from the breast parenchyma and is not associated with radiation exposure.


name: Metastatic HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has spread to another anatomic site.


name: Recurrent HER2-Positive Breast Carcinoma

description: The reemergence of HER2-positive breast carcinoma after a period of remission.


Anatomic Stage 0 Breast Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Stage IIIC Breast Cancer AJCC v6

description: Stage IIIC Breast Cancer was added in the 6th Edition AJCC Staging Manual, on the basis of metastasis to the infraclavicular lymph nodes (N3) plus any T, M0.


name: Hormone Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for hormone receptors.


name: Refractory Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.


breast leiomyosarcoma

description: An aggressive malignant smooth muscle neoplasm, arising from the breast. It is characterized by a proliferation of neoplastic spindle cells.


Malignant nipple neoplasm male

description: A malignant neoplasm that affects the area of the nipple in males.


name: Metastatic Breast Neuroendocrine Neoplasm

description: A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.


name: Inflammatory carcinoma of breast stage III

description: Inflammatory breast carcinoma is classified as AJCC Stage IIIB (T4d) unless other criteria indicate more advanced staging.


name: High Grade Breast Mucoepidermoid Carcinoma

description: An aggressive mucoepidermoid carcinoma that arises from the breast. It is characterized by the presence of focal necrosis and high mitotic activity. Lymph node and distant metastases are common. The prognosis is usually poor.


Postradiation Breast Angiosarcoma

description: A malignant vascular neoplasm arising from the skin of the breast secondary to radiation treatment for breast cancer.


name: Progesterone Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for progesterone receptors.


name: Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma

description: An invasive ductal breast carcinoma associated with an invasive lobular carcinomatous component.


name: Metastatic Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Multicentric Breast Carcinoma

description: A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.


name: Breast Cancer by AJCC v8 Prognostic Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)


Stage IIIB Breast Carcinoma

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Locally Advanced HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Prognostic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Male Breast Carcinoma

description: A rare invasive carcinoma that arises from the male breast. Morphologically, it is similar to the invasive carcinomas that arise from the female breast. It usually develops in the retroareolar region.


Anatomic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Low Grade Breast Adenosquamous Carcinoma

description: A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.


name: Refractory Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is resistant to treatment.


name: Noninfiltrating intraductal papillary adenocarcinoma (morphologic abnormality)

description: Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)


HER2-Low Breast Carcinoma

description: A breast adenocarcinoma defined by low expression of HER2 (IHC1+ or IHC2+; FISH negative).


name: Metastatic Breast Signet Ring Cell Carcinoma

description: A signet ring cell carcinoma that arises from the breast and has metastasized to other anatomic sites.


Breast adenocarcinoma metastatic

description: An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.


name: Recurrent Estrogen Receptor-Positive Breast Carcinoma

description: The reemergence of estrogen receptor-positive breast carcinoma after a period of remission.


Stage II Breast Cancer AJCC v6 and v7

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


name: Inflammatory carcinoma of breast recurrent

description: The reemergence of inflammatory carcinoma of the breast after a period of remission


name: Breast Carcinoma with Choriocarcinomatous Features

description: An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.


name: Prognostic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Carcinoma in situ of female breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the female breast.


name: Intraductal papillary adenocarcinoma with invasion

description: A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.


Recurrent Breast Angiosarcoma

description: The reemergence of breast angiosarcoma after a period of remission.


name: Anatomic Stage IIA Breast Cancer AJCC v8

description: Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Malignant neoplasm of nipple of female breast

description: A malignant neoplasm that affects the area of the nipple in females.


name: Paget's disease and infiltrating duct carcinoma of breast

description: Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Anatomic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Recurrent Breast Medullary Carcinoma

description: The reemergence of breast medullary carcinoma after a period of remission.


name: Invasive Breast Lobular Carcinoma, Tubulolobular Variant

description: An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.


name: Hormone Receptor-Negative Breast Carcinoma

description: Breast adenocarcinoma that is negative for hormone receptors.


name: Locally Advanced Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Breast sarcoma recurrent

description: The reemergence of breast sarcoma after a period of remission.


name: Breast Carcinoma with Osseous Metaplasia

description: An invasive breast carcinoma showing differentiation towards bone structures.


Breast Polymorphous Adenocarcinoma

description: A rare, low grade malignant epithelial neoplasm arising from the breast. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern.


Stage III Breast Cancer AJCC v7

description: Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


BRCA-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


name: Unresectable Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that is not amenable to surgical resection.


name: Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component

description: An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.


name: Prognostic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Pleomorphic lobular carcinoma in situ of breast

description: Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.


name: Invasive micropapillary carcinoma of breast

description: An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.


name: Anatomic Stage IIIB Breast Cancer AJCC v8

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Unilateral Breast Carcinoma

description: Breast carcinoma of one breast, or one side of the breast.


Childhood Malignant Breast Neoplasm

description: A malignant neoplasm that affects the breast and occurs during childhood.


Carcinoma in situ of male breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the male breast. It includes the entire spectrum of carcinoma in situ observed in the female breast. It usually develops in the retroareolar region.


name: Paget's disease and intraductal carcinoma of breast

description: Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.


Stage III Breast Cancer AJCC v6

description: Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Metastatic Breast Lobular Carcinoma

description: A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Breast Adenocarcinoma

description: Breast adenocarcinoma that does not respond to treatment.


name: Invasive Breast Carcinoma by Histologic Grade


Unresectable Breast Carcinoma

description: Breast carcinoma that is not amenable to surgical resection.


name: Recurrent HER2-Negative Breast Carcinoma

description: The reemergence of HER2-negative breast adenocarcinoma after a period of remission.


Breast adenocarcinoma recurrent

description: The reemergence of breast adenocarcinoma after a period of remission.


name: Locally Advanced HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


PALB2-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in the PALB2 gene.


name: Recurrent Invasive Breast Carcinoma of No Special Type

description: The reemergence of invasive breast carcinoma of no special type after a period of remission.


Metastatic Breast Carcinoma

description: A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Breast Lymphoma

description: Breast lymphoma that is resistant to treatment.


name: Breast Ductal Carcinoma In Situ, Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.


Occult Breast Carcinoma

description: Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.


name: Prognostic Stage III Breast Cancer AJCC v8

description: Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: solid type ductal carcinoma in situ of breast

description: Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.


Malignant nipple neoplasm

description: A malignant neoplasm that affects the area of the nipple.


Recurrent Breast Papillary Carcinoma

description: The reemergence of breast papillary carcinoma after a period of remission.


breast liposarcoma

description: A malignant adipose tissue neoplasm of the breast.


name: Prognostic Stage IV Breast Cancer AJCC v8

description: Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


name: Metastatic Androgen Receptor-Positive Breast Carcinoma

description: Androgen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


breast sarcoma

description: A malignant mesenchymal neoplasm that arises from the breast. Representative examples include angiosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and extraskeletal osteosarcoma.


Breast Carcinoma Metastatic in the Lung

description: A carcinoma that arises from the breast and has metastasized to the lung.


Invasive Breast Apocrine Carcinoma

description: An invasive breast adenocarcinoma with cytological and immunophenotypic characteristics of apocrine differentiation in more than 90 percent of the malignant cells.


name: Anatomic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Triple-Negative Breast Inflammatory Carcinoma

description: Triple-negative breast inflammatory carcinoma that has spread from its original site of growth to another anatomic site.


Carcinoma breast stage I

description: Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003


name: Breast Tall Cell Carcinoma with Reversed Polarity

description: A rare subtype of invasive breast carcinoma characterized by tall columnar cells with reversed nuclear polarity, arranged in solid and solid papillary patterns, most commonly associated with IDH2 p.Arg172 hotspot mutations. (WHO 2019)


name: Androgen Receptor-Positive Breast Carcinoma

description: Breast carcinoma that is positive for androgen receptors.


name: Synchronous Ipsilateral Breast Carcinoma

description: Diagnosis of more than one distinct tumor focus in the same breast, within two months.


name: Resectable Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is amenable to surgical resection.


name: Prognostic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Anatomic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Grade 1 Invasive Breast Carcinoma

description: A well differentiated invasive breast carcinoma.


name: Unresectable HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that is not amenable to surgical resection.


Secondary malignant neoplasm of breast

description: The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.


Grade 3 Invasive Breast Carcinoma

description: A poorly differentiated invasive breast carcinoma.


name: Unresectable Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that is not amenable to surgical resection.


Stage IB Breast Cancer AJCC v7

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast rhabdomyosarcoma

description: A malignant mesenchymal tumor with skeletal muscle differentiation affecting the breast.


Breast Cancer by AJCC v7 Stage

description: A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 7th edition.


Stage IIB Breast Carcinoma

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0).  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Anatomic Stage IB Breast Cancer AJCC v8

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Breast Ductal Carcinoma In Situ and Lobular Carcinoma

description: A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.


breast extraskeletal osteosarcoma

description: An osteosarcoma arising from the breast tissue.


name: Recurrent Breast Ductal Carcinoma In Situ

description: The reemergence of breast ductal carcinoma in situ after a period of remission.


name: Breast Ductal Carcinoma In Situ, Non-Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells without evidence of central necrosis or cell death.


name: Locally Advanced Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Invasive Breast Lobular Carcinoma, Signet Ring Variant

description: An invasive lobular carcinoma characterized by the presence of malignant epithelial cells with large intracytoplasmic lumina that cause displacement of the nuclei towards one pole of the cells.


name: Prognostic Stage I Breast Cancer AJCC v8

description: Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Anatomic Stage IIIA Breast Cancer AJCC v8

description: Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Breast Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the breast parenchyma and has metastasized to other anatomic sites.


Invasive papillary breast carcinoma

description: An invasive breast carcinoma characterized by the presence of papillary structures.


name: adenocarcinoma of breast with spindle cell metaplasia

description: An invasive adenocarcinoma of the breast usually affecting post-menopausal women, characterized by extensive spindle cell metaplasia of the neoplastic glandular cells.


name: Recurrent Progesterone Receptor-Positive Breast Carcinoma

description: The reemergence of progesterone receptor-positive breast carcinoma after a period of remission.


Metastatic Breast Carcinoma in the Skin

description: A carcinoma that arises from the breast and has metastasized to the skin.


Unresectable HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that is not amenable to surgical resection.


name: Ductal Carcinoma In Situ with Microinvasion

description: Invasive breast carcinoma measuring 1 mm or less in size.


Early Stage Breast Carcinoma

description: Breast carcinoma that has not spread beyond the breast and the axillary lymph nodes.


Anatomic Stage IV Breast Cancer AJCC v8

description: Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Unresectable Breast Adenocarcinoma

description: A breast adenocarcinoma that is not amenable to surgical resection.


name: Unresectable Breast Inflammatory Carcinoma

description: Inflammatory breast carcinoma that is not amenable to surgical resection.


Invasive Female Breast Carcinoma

description: An invasive carcinoma that arises from the breast in females.


name: Refractory HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that is resistant to treatment.


name: Breast Carcinoma with Chondroid Metaplasia

description: An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.


Metastatic HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that has spread from its original site of growth to another anatomic site.


malignant breast phyllodes tumor

description: A phyllodes tumor of the breast characterized by infiltrative margins and a sarcomatous stromal component. The sarcomatous stroma usually displays features of fibrosarcoma. Liposarcomatous, osteosarcomatous, or rhabdomyosarcomatous elements may also be present.


Hereditary Male Breast Carcinoma

description: Breast carcinoma that has developed in male relatives of patients with history of breast carcinoma.


Recurrent Breast Paget Disease

description: The reemergence of Paget disease of the breast after a period of remission.


name: Early Stage Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that has not spread beyond the breast or axillary lymph nodes.


Locally Advanced Breast Adenocarcinoma

description: Breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Childhood Breast Carcinoma

description: A rare breast carcinoma that occurs during childhood.


name: Breast Ductal Carcinoma with Squamous Metaplasia

description: An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the ductal carcinomatous component.


name: Metastatic Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Stage IA Breast Cancer AJCC v7

description: Stage IA includes: T1, N0, M0.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast lymphoma

description: A lymphoma that arises from the breast. There is no history of extramammary breast lymphoma and ipsilateral axillary lymph node involvement does not exclude the diagnosis of primary breast lymphoma. Most patients present with a painless breast lump. The vast majority of cases are B-cell non-Hodgkin lymphomas. Diffuse large B-cell lymphoma, follicular lymphoma, and extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue are the most common types of primary non-Hodgkin lymphoma of the breast. Primary Hodgkin lymphoma of the breast is rare.


name: Invasive Breast Lobular Carcinoma, Pleomorphic Variant

description: A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.


Breast Cancer by AJCC v8 Anatomic Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)


Breast cancer recurrent

description: The reemergence of carcinoma in the breast after a period of remission.


Breast Mixed Carcinoma

description: An invasive breast carcinoma characterized by the presence of more than one malignant epithelial histologic pattern.


name: Breast Carcinoma with Melanotic Features

description: A very rare primary malignant tumor of the breast, characterized by an invasive breast carcinoma that co-exists with a melanoma component.  The vast majority of melanotic tumors that affect the breast are metastatic melanomas that originate in extra-mammary sites.


name: Breast Paget Disease without Invasive Carcinoma

description: Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.


Refractory Breast Carcinoma

description: Breast carcinoma that does not respond to treatment.